Invega Sustenna vs Latuda
Side-by-side cost comparison based on Medicare Part D data
Invega Sustenna
Paliperidone Palmitate
Manufactured by Janssen
Latuda
Lurasidone
Manufactured by Sunovion
Latuda costs 80% less per claim than Invega Sustenna ($300.00 vs $1,513.00). A generic version of Latuda is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Invega Sustenna | Latuda |
|---|---|---|
| Avg Cost Per Claim | $1,513.00 | $300.00 |
| Total Medicare Spending | $1.9B | $1.4B |
| Total Beneficiaries | 148,000 | 512,000 |
| Total Claims | 1,240,000 | 4,560,000 |
| Annual Cost/Patient | $12,676.00 | $2,670.00 |
| Year-over-Year Change | +4.2% | -32.5% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Feb 19, 2023 |
| Manufacturer | Janssen | Sunovion |
| Condition | Mental Health | Mental Health |
| Generic Name | Paliperidone Palmitate | Lurasidone |
Invega Sustenna vs Latuda: What the Data Shows
Invega Sustenna (Paliperidone Palmitate) and Latuda (Lurasidone) are both used to treat mental health. Based on Medicare Part D data, Latuda costs $300.00 per claim, which is 80% less than Invega Sustenna at $1,513.00 per claim.
Medicare spent $1.9B on Invega Sustenna and $1.4B on Latuda. In terms of patient reach, Latuda serves more beneficiaries (512,000 vs 148,000).
Year-over-year spending changed +4.2% for Invega Sustenna and -32.5% for Latuda.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Latuda is cheaper at $300.00 per claim, compared to $1,513.00 for Invega Sustenna. That makes Latuda about 80% less expensive per claim based on Medicare Part D data.
Yes, both Invega Sustenna and Latuda are used to treat mental health. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Paliperidone Palmitate and generic Lurasidone can offer significant cost savings, typically 80-95% less than the brand name.
Medicare Part D spent $1.9B on Invega Sustenna covering 148,000 beneficiaries, and $1.4B on Latuda covering 512,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both Invega Sustenna and Latuda. What follows is the interpretation — which specific axes carry the most weight for Invega Sustenna versus Latuda, and which differences are large enough to influence a real decision.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.